Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q1 CY2025, with ...

Set to be banned outright by the Food and Drug Administration next year, Primatene Mist has already become scarce because of a shortage of a material used to make it.

Q4 sales rose 20% YoY to $186.5M, missing estimates of $188.81M; adjusted EPS was $0.92, below the $0.94 consensus. Primatene MIST topped $100M in annual sales, with $29M in Q4; Baqsimi posted $41 ...

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) achieved a 14% increase in annual revenues, reaching $732 million for the 2024 fiscal year. The company recorded a solid 5% year-over-year growth in the ...

Primatene Mist achieved its highest quarterly sales since launch, reaching $26 million, marking significant progress towards the company's goal of $100 million in annual sales by the end of 2024.

Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in ...

Importantly, Primatene Mist surpassed our long-term annual sales target of $65 million, with sales growth of 60% in the fourth quarter of -- to $21.5 million from $13.4 million for the same period ...

"The surprising reintroduction of Primatene Mist in the United States" Annals ATS 2019; DOI: 10.1513/AnnalsATS.201902-164HP. Share on Facebook. Opens in a new tab or window.

Primatene Mist is now back on pharmacy shelves and is the only over-the-counter medicine available for mild, intermittent asthma symptoms. In their column, Joe and Teresa Graedon answer letters ...

(RTTNews) - After 7 years of absence, asthma inhaler Primatene Mist, developed by Amphastar Pharmaceuticals, is reentering the market with renewed features. The over-the-counter epinephrine ...